Bone Therapeutics announces 2021 full year results Strategic focus revised and fully focused on achieving topline results of the ALLOB Phase IIb study in tibial fracturesDiscussions for ALLOB global partnership still ongoingBoard of Directors and Management exploring all strategic options to protect shareholder.
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it is redefining its strategic priorities to concentrate specifically on the development of its most advanced clinical asset, the allogeneic cell therapy .